Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 8Phase 1/2 4Phase 3 2

Status

Recruiting 8Completed 8Active not recruiting 6Withdrawn 4Terminated 4Not yet recruiting 2Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 3Leukemia, Myeloid, Acute 2Recurrence 1Neoplasm, Residual 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × daratumumab × Clear all
NCT04824794 2026-05-19

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Genmab

Phase 1/2 Terminated
130 enrolled 40 charts
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT05590377 2026-01-30

iinnovate-3

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Terminated
15 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT03537599 2025-05-21

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
4 enrolled 7 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated
56 enrolled 22 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡